Stock INCY INCYTE CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Incyte Corporation Stock

Equities

INCY

US45337C1027

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2025-01-23 pm EST 		5-day change 1st Jan Change
72.53 USD +0.17% Intraday chart for Incyte Corporation +0.08% +5.01%
Jan. 22 RBC Adjusts Price Target on Incyte to $70 From $75, Maintains Sector Perform Rating MT
Jan. 16 Sector Update: Health Care Stocks Flat to Lower Premarket Thursday MT

Valuation: Incyte Corporation

Capitalization 13.97B 13.42B 12.69B 11.32B 20.09B 1,208B 22.25B 154B 56.58B 498B 52.39B 51.33B 2,180B P/E ratio 2024 *
189x
P/E ratio 2025 * 14.9x
Enterprise value 11.41B 10.96B 10.36B 9.25B 16.4B 986B 18.17B 126B 46.2B 407B 42.78B 41.91B 1,780B EV / Sales 2024 *
2.72x
EV / Sales 2025 * 2.21x
Free-Float
97.95%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Incyte Corporation

Dynamic Chart

Latest news: Incyte Corporation

RBC Adjusts Price Target on Incyte to $70 From $75, Maintains Sector Perform Rating Jan. 22 MT
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday Jan. 16 MT
Incyte, Syndax Receive FDA Approval for Niktimvo to Treat Chronic Graft-Versus-Host Disease Jan. 16 MT
Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes Jan. 15 DJ
Incyte and Syndax Pharmaceuticals Announce U.S. Food and Drug Administration Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes Jan. 15 CI
Incyte Corporation Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 10:30 AM Jan. 13
Incyte Corporation Announces Retirement of Barry P. Flannelly as Executive Vice President, Effective July 31, 2025 Jan. 10 CI
RBC Lifts Price Target on Incyte to $75 From $74, Keeps Sector Perform Rating Jan. 07 MT
Wells Fargo Adjusts Incyte's Price Target to $70 From $68, Keeps Equalweight Rating Dec. 19 MT
UBS Initiates Coverage on Incyte With Neutral Rating, $77 Price Target Dec. 17 MT
Leerink Adjusts Price Target on Incyte to $100 From $87, Maintains Outperform Rating Dec. 16 MT
Incyte Corporation - Shareholder/Analyst Call Dec. 12
Incite Says Phase 3 Trial of Monjuvi in Follicular Lymphoma Patients Meets Endpoints Dec. 10 MT
More news

Last Transcript: Incyte Corporation

Logo Incyte Corporation
Incyte Corporation Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 10:30 AM
Jan. 13
More transcripts

Analysts' recommendations: Incyte Corporation

RBC Adjusts Price Target on Incyte to $70 From $75, Maintains Sector Perform Rating Jan. 22 MT
RBC Lifts Price Target on Incyte to $75 From $74, Keeps Sector Perform Rating Jan. 07 MT
Wells Fargo Adjusts Incyte's Price Target to $70 From $68, Keeps Equalweight Rating Dec. 19 MT
UBS Initiates Coverage on Incyte With Neutral Rating, $77 Price Target Dec. 17 MT
Leerink Adjusts Price Target on Incyte to $100 From $87, Maintains Outperform Rating Dec. 16 MT
More recommendations

Press Releases: Incyte Corporation

Incyte to Report Fourth Quarter and Year-End 2024 Financial Results Jan. 21 BU
Incyte and Syndax Announce U.S. Food and Drug Administration Approval of Niktimvo 9 mg and 22 mg Vial Sizes Jan. 16 AQ
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes Jan. 15 PR
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference Jan. 14 AQ
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference Jan. 13 BU
More press releases

News in other languages: Incyte Corporation

Aktuelle Incyte Tafasitamab (Monjuvi® ) Daten demonstrieren auf dem ASH 2024 deutlich verbessertes progressionsfreies Überleben bei Patienten mit rezidiviertem oder refraktärem follikulärem Lymphom Dec. 12
Les données de dernières minutes d'Incyte sur le tafasitamab (Monjuvi®) à l'ASH 2024 démontrent une survie sensiblement améliorée de la survie sans progression chez les patients atteints de lymphome folliculaire récidivant ou réfractaire Dec. 12
Data Center-Boom: Wer profitiert? Dec. 06
Borsa svizzera: chiude in ribasso, SMI -0,43% Dec. 04
Incyte stellt auf der ASH-Jahrestagung 2024 neue Daten vor, darunter eine brandaktuelle mündliche Präsentation zu Tafasitamab bei follikulärem Lymphom Nov. 26
More news

Quotes and Performance

1 day+0.17%
1 week+0.08%
Current month+5.01%
1 month+3.85%
3 months+11.29%
6 months+10.23%
Current year+5.01%
More quotes

Course Extremes

1 week
71.05
Extreme 71.05
73.98
1 month
67.70
Extreme 67.7
75.04
Current year
68.92
Extreme 68.92
75.04
1 year
50.35
Extreme 50.3498
83.95
3 years
50.27
Extreme 50.27
86.29
5 years
50.27
Extreme 50.27
110.37
10 years
50.27
Extreme 50.27
153.15
More quotes

Managers and Directors: Incyte Corporation

Director TitleAgeSince
Herve Hoppenot CEO
 Chief Executive Officer 65 2014-01-12
Christiana Stamoulis DFI
 Director of Finance/CFO 54 2019-02-10
Pablo Cagnoni CTO
 Chief Tech/Sci/R&D Officer 61 2023-06-04
Manager TitleAgeSince
Julian Baker BRD
 Director/Board Member 58 2000-12-31
Herve Hoppenot CHM
 Chairman 65 2015-05-21
Jean-Jacques Bienaimé BRD
 Director/Board Member 71 2015-01-19
More insiders

ETFs: Incyte Corporation

Name Weight AuM 1st Jan change Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
14.55% 335 M€ -4.38% -
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD ETF First Trust NYSE Arca Biotechnology ETF - CAD
2.94% 1 M€ 0.00% -
LEVERAGE SHARES 1X ARK GENOMIC TRACKER ETP - USD ETF Leverage Shares 1x ARK Genomic Tracker ETP - USD
2.88% 1 M€ 0.00% -
More ETFs: Incyte Corporation

Biopharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
INCYTE CORPORATION Stock Incyte Corporation
+0.17%+0.08%+17.23%-3.02%13.97B
CSL LIMITED Stock CSL Limited
+0.74%-1.11%-6.66%+3.59%82.08B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.85%+5.30%+31.79%+28.73%52.22B
UCB Stock UCB
+0.38%-3.92%+116.75%+101.67%36.3B
BIOGEN INC. Stock Biogen Inc.
+0.64%+1.73%-42.92%-34.85%20.94B
INTRA-CELLULAR THERAPIES, INC. Stock Intra-Cellular Therapies, Inc.
-0.06%+0.64%+91.20%+197.87%13.5B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+1.46%+11.22%+356.58%+636.99%12.89B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-0.32%-0.87%+6.26%-40.81%11.87B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
+0.27%+1.53%-33.16%-26.53%11.85B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-0.18%+1.82%+17.81%+83.41%10.48B
Average +0.70%+1.48%+55.49%+94.70% 26.61B
Weighted average by Cap. +1.15%+0.43%+39.04%+58.88%
See all sector performances

Financials

2024 *2025 *
Net sales 4.2B 4.03B 3.81B 3.4B 6.04B 363B 6.69B 46.27B 17.01B 150B 15.75B 15.43B 655B 4.64B 4.46B 4.22B 3.76B 6.67B 401B 7.39B 51.15B 18.8B 165B 17.41B 17.05B 724B
Net income 77.62M 74.56M 70.49M 62.91M 112M 6.71B 124M 855M 314M 2.77B 291M 285M 12.11B 975M 937M 886M 790M 1.4B 84.31B 1.55B 10.74B 3.95B 34.76B 3.66B 3.58B 152B
Net Debt -2.56B -2.46B -2.33B -2.08B -3.68B -222B -4.08B -28.23B -10.38B -91.33B -9.61B -9.41B -400B -3.7B -3.56B -3.36B -3B -5.32B -320B -5.9B -40.79B -14.99B -132B -13.88B -13.6B -578B
More financial data * Estimated data

Company Profile

Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).
Employees
2,524
Sector
Pharmaceuticals
Calendar
2025-02-10 - Q4 2024 Earnings Release
More about the company

Quotes

Date Price Change Volume
25-01-23 72.53 $ +0.17% 1,042,544
25-01-22 72.41 $ -1.44% 1,165,716
25-01-21 73.47 $ +2.14% 1,867,891
25-01-17 71.93 $ -0.75% 1,013,332
25-01-16 72.47 $ +0.01% 1,100,000

Delayed Quote Nasdaq, January 23, 2025 at 04:00 pm EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart INCYTE-CORPORATION More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
AA
surperformance-ratings-light-chart INCYTE-CORPORATIONMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
72.53USD
Average target price
79.76USD
Spread / Average Target
+9.96%
Consensus
Profit revisions
estimates-change-chart INCYTE-CORPORATION Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart INCYTE-CORPORATION Company calendar
  1. Stock Market
  2. Equities
  3. INCY Stock